Exscientia plc (EXAI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMIL Summary
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve the new-drug discovery process with artificial intelligence.
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, according to a statement seen by Reuters.
Exscientia plc Profile
| - Industry | - Sector | Dr. David Hallett Ph.D. CEO | NASDAQ (NGS) Exchange | US30223G1022 ISIN |
| US Country | 483 Employees | - Last Dividend | - Last Split | 1 Oct 2021 IPO Date |
Overview
Exscientia plc is an innovative Pharma-tech entity distinguished by its use of artificial intelligence (AI) to spearhead the creation of novel medications. Specifically targeting diseases that presently lack adequate treatments, this company endeavors to meet these significant unmet patient needs through advanced AI-driven methodologies. Since its establishment in 2012, Exscientia has been at the forefront of integrating AI into the pharmaceutical development process, positioning itself as a pioneering force in the field. Headquartered in Oxford, the United Kingdom, the company has forged valuable collaboration agreements with industry giants and institutions such as Merck KGaA, Bristol Myers Squibb, Sanofi, the Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics, demonstrating its esteemed position in the sector and its commitment to addressing critical health challenges through innovative partnerships.
Products and Services
Exscientia is actively involved in the development of a diverse portfolio of therapeutic candidates across various stages of the drug development process, including:
- GTAEXS617 (CDK7 Inhibitor): Positioned as the company's leading product contender, this molecule is currently engaging in a Phase 1/2 trial. Its development is geared towards managing potential toxicities related to CDK7, while also fine-tuning pharmacokinetics to enhance on-target efficacy, showing promise for diseases that could benefit from CDK7 inhibition.
- EXS4318 (PKC-theta Inhibitor): This compound is under Phase 1 clinical investigation for its potential in treating inflammation and immunology-related conditions. By inhibiting PKC-theta, EXS4318 represents a strategic approach to modulating immune responses in various diseases.
- EXS74539 (LSD1 Inhibitor): Currently in preclinical studies, EXS74539 targets LSD1, a therapeutic approach for SCLC (Small Cell Lung Cancer), AML (Acute Myeloid Leukemia), and potentially other indications. Its development underscores Exscientia’s commitment to exploring solutions for challenging cancers.
- EXS73565 (MALT1 Inhibitor): This molecule, also in the preclinical study phase, is being explored for its potential in treating multiple hematology indications through the inhibition of MALT1, highlighting Exscientia's efforts in addressing hematological malignancies.
- DSP-0038: Undergoing Phase 1 studies, DSP-0038 is part of Exscientia’s pipeline exploring new frontiers in therapeutic development, reflecting the company’s dedication to innovation in drug discovery and development.
Contact Information
